Tag: bispecific antibodies
Risvutatug Rezetecan Demonstrates Overall Survival Benefit Over Topotecan in Relapsed Small...
Interim results from the pivotal Phase 3 ARTEMIS-008 trial (NCT06498479) show that risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, significantly reduced the risk of death...
Recent Trends of ADCs
Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer therapeutics, offering significant advancements over traditional treatments. The global ADC market is projected to reach $11.29 billion in 2023, with an estimated compound annual growth rate (CAGR) of 9.2% between 2024 and 2030, reflecting substantial economic and scientific interest in this field
Developing ‘Next-Gen’ Therapeutics: a First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC
Bispecific ADCs (bsADCs) are positioned as an emerging, next-generation, class of therapeutics, combining the dual-targeting capabilities of bispecific antibodies (bsAbs) with the potent cytotoxicity of antibody-drug conjugates (ADCs). The resulting bsADC offers improved efficacy and safety for the treatment of heterogeneous solid tumors.
Bispecific Antibody Evolution for Cancer Therapy: Advances from Merus, Adimab, Regeneron,...
The concept of using bispecific antibodies for tumor therapy has been developed more than 30 years ago with many initial struggles. However, new developments...
Merus Therpeutics: Seeking to Advance Immuno-Oncology
In Oncology, many new developments of the last decade have made it possible to treat cancers in ways that are better-targeted, more potent, and...
Sneaking Medicines Across the Blood-Brain Barrier
Research published in the November 2014 edition of The FASEB Journal, published by the Federation of the American Societies for Experimental Biology, suggests that a very small single domain antibody called FC5 has proven able to cross the blood-brain barrier (BBB). This opens the door to new treatments for a multitude of brain diseases.
